Assessing Nasal Function in Chronic Rhinosinusitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the role of acquired Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) deficiency in the development of Chronic Rhinosinusitis (CRS). Participants will undergo Nasal Potential Difference (NPD) measurements, which assess CFTR-dependent ion transport through a series of perfusions in the nasal cavities. The study will utilize a 4-Step protocol to evaluate the bioelectric responses of the nasal epithelium, monitored against a reference electrode. A multidisciplinary committee will oversee the safety and integrity of the study, ensuring that participants meet specific health criteria.

Why it matters

Who can join: the full rules

The patient eligibility criteria are designed to limit enrollment to healthy individuals and patients who clearly have CRS based on Sinus and Allergy health partnership criteria, but who are sufficiently well (both in terms of CRS and in terms of concomitant illness, such as asthma) to safely participate in study procedures and provide interpretable results.

Inclusion Criteria:

a. Patients with CRS will be diagnosed according to Sinus and Allergy Health Partnership symptom-based and objective criteria as follows: i. Duration of disease is qualified by continuous symptoms (≥ 2 major factors or at least 1 major factor \& 2 minor symptoms; Table 2) for ≥ 12 consecutive weeks or ≥ 12 weeks of physical findings. ii. One of these signs of inflammation must be present and identified in association with ongoing symptoms.

1. Discolored nasal drainage arising from the nasal passages, nasal polyps, or polypoid swelling as identified on physical examination with nasal endoscopy.
2. Edema or erythema of the middle meatus or ethmoid bulla
3. Generalized or localized erythema or edema. If it does not involve the middle meatus or ethmoid bulla, CT scan is performed to confirm a diagnosis.
4. The CT scan must demonstrate isolated or diffuse mucosal thickening, bone changes, air-fluid levels. b. Age ≥ 19 years and Weight ≥ 50 kg c. Ability to perform NPD testing d. Negative pregnancy test (for females of childbearing potential) e. Written informed consent

Exclusion Criteria:

1. Acute illness within 2 weeks before start of study treatment.
2. History of major asthma attack within 2 months prior to start of study treatment.
3. Change in intranasal medications (including use of corticosteroids, cromolyn, atrovent, phenylephrine, or oxymetazoline) within 14 days prior to start of study treatment.
4. Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test.
5. Hemoglobin \<10 gm/dL and Serum albumin \<2.5 g/dL.
6. Abnormal liver function (serum ALT, AST, alkaline phosphatase, or total bilirubin \>2 times upper limit of normal).
7. Abnormal renal function (serum creatinine \>1.5 times upper limit of normal).
8. Pregnancy or breast feeding.
9. History of solid organ or hematological transplantation
10. History of autoimmune or granulomatous disorder.

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting

Study contacts

• Principal investigator: Brad Woodworth, MD — University of Alabama at Birmingham
• Study coordinator: Norma Miller, RN
• Email: ncmiller@uabmc.edu
• Phone: (205) 975-6169

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Post-marketing follow-up of four devices for acute viral rhinitis and related conditions

  This study tests four medical devices (NS, NHE, NHG, and PIR) in real-life use to see if they are safe, tolerated, and helpful for people with acute viral rhinitis, rhinosinusitis, or rhinopharyngitis.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07383493

• Understanding how brain changes relate to smell disorders over time

  This small, year-long study tests how brain activity and smell-related inflammation relate to different smell disorders in adults.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07149428

• Testing Raphamin for treating acute rhinosinusitis in adults

  This study is testing if a new medication called Raphamin can help adults with acute rhinosinusitis feel better and improve their quality of life.

  Recruiting at 4 sites Phase 3 Materia Medica Holding · Aramil and 43 other locations · NCT06901297

• Seawater nasal spray with essential oils for short-term relief of blocked nose from acute rhinitis

  This test will try a seawater nasal spray enriched with essential oils in people aged 12 and older who have a blocked nose from acute rhinitis to see if it improves symptoms over 7 days.

  Recruiting Laboratoires Gilbert · Bayeux and 2 other locations · NCT06580210

• Assessment of a decongestant seawater spray with essential oils for nasal obstruction

  This study is testing a new seawater spray with essential oils to see if it helps people aged 12 and older who have nasal congestion from colds or allergies breathe easier.

  Recruiting at 3 sites Laboratoires Gilbert · Blainville-sur-Orne and 4 other locations · NCT05494346

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.